Cervical Cancer Screening Test Receives Approval for the European Sector
|
By LabMedica International staff writers Posted on 09 Sep 2014 |
|
Image: Example of chromosomes stained with the FHACT combination probe: 3q26 (TERC) (red), 5p15 (D5S2095) (green), 20q13 (D20S911) (gold), and CEP7 (aqua) (Photo courtesy of Cancer Genetics Inc.).
A screening test that detects the clonal chromosomal aberrations (gains or amplifications) commonly found in cervical cancer specimens has received CE-marking that allows it to be distributed as a diagnostic test in the 28 countries making up the European Economic Area.
The Cancer Genetics Inc. (Rutherford, NJ, USA) FISH (fluorescence in situ hybridization)-based HPV-Associated Cancer Test (FHACT) utilizes the only four color FISH probe that can be used for cervical cancer screening as additional triage before referral for colposcopy.
The FISH analysis is performed on nuclei of cells derived from a liquid pap specimen using the FHACT combination probe manufactured by CGI Italia (Milan, Italy), a wholly owned subsidiary of Cancer Genetics Inc. The probe comprises 3q26 (TERC) (red), 5p15 (D5S2095) (green), 20q13 (D20S911) (gold), and CEP7 (aqua).
The FISH probe has been optimized to identify copy number gains of 3q26, 5p15, chromosome 7, and 20q13. In normal diploid interphase and metaphase cells, FHACT generates two red, two green, two blue, and two gold signals corresponding to the normal chromosomes 3, 5, 7 and 20 respectively. In cells with gain or amplification of 3q26, 5p15, 20q13 and/or chromosome 7, the number of red, green, gold, and/or blue signals will be greater than two each.
The FHACT test identifies irreversible genomic changes associated with progression to cancer. In addition to identifying those women most at risk for cervical disease, it can help reduce unnecessary, invasive testing and over-treatment in women who do not show the genomic abnormalities associated with disease progression.
"We are committed to the highest level of quality in the development and manufacture of our DNA-FISH probes and tests. Our probes are manufactured to meet or exceed all established quality and performance specifications, and comply with relevant safety and regulatory requirements in order to qualify them for CE marking," said Panna Sharma, CEO of Cancer Genetics, Inc. "Cervical cancer screening is evolving, but there remains a need for more definitive and genomically informed diagnosis. Our proprietary cervical cancer test, FHACT, was designed in response to this need. Having it affixed with the CE-mark will allow us to expand our marketing and sales in Europe, and allow for greater adoption of the test globally."
The FHACT method is protected by several US and international patents.
Related Links:
Cancer Genetics Inc.
CGI Italia
The Cancer Genetics Inc. (Rutherford, NJ, USA) FISH (fluorescence in situ hybridization)-based HPV-Associated Cancer Test (FHACT) utilizes the only four color FISH probe that can be used for cervical cancer screening as additional triage before referral for colposcopy.
The FISH analysis is performed on nuclei of cells derived from a liquid pap specimen using the FHACT combination probe manufactured by CGI Italia (Milan, Italy), a wholly owned subsidiary of Cancer Genetics Inc. The probe comprises 3q26 (TERC) (red), 5p15 (D5S2095) (green), 20q13 (D20S911) (gold), and CEP7 (aqua).
The FISH probe has been optimized to identify copy number gains of 3q26, 5p15, chromosome 7, and 20q13. In normal diploid interphase and metaphase cells, FHACT generates two red, two green, two blue, and two gold signals corresponding to the normal chromosomes 3, 5, 7 and 20 respectively. In cells with gain or amplification of 3q26, 5p15, 20q13 and/or chromosome 7, the number of red, green, gold, and/or blue signals will be greater than two each.
The FHACT test identifies irreversible genomic changes associated with progression to cancer. In addition to identifying those women most at risk for cervical disease, it can help reduce unnecessary, invasive testing and over-treatment in women who do not show the genomic abnormalities associated with disease progression.
"We are committed to the highest level of quality in the development and manufacture of our DNA-FISH probes and tests. Our probes are manufactured to meet or exceed all established quality and performance specifications, and comply with relevant safety and regulatory requirements in order to qualify them for CE marking," said Panna Sharma, CEO of Cancer Genetics, Inc. "Cervical cancer screening is evolving, but there remains a need for more definitive and genomically informed diagnosis. Our proprietary cervical cancer test, FHACT, was designed in response to this need. Having it affixed with the CE-mark will allow us to expand our marketing and sales in Europe, and allow for greater adoption of the test globally."
The FHACT method is protected by several US and international patents.
Related Links:
Cancer Genetics Inc.
CGI Italia
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
Automatic CLIA Analyzer
Shine i9000
Capillary Blood Collection Tube
IMPROMINI M3
Latest Pathology News
- Tears Offer Noninvasive Alternative for Diagnosing Neurodegenerative Diseases
- AI-Powered Method Combines Blood Data to Accurately Measure Biological Age
- AI Tool Detects Cancer in Blood Samples In 10 Minutes
- AI Pathology Analysis System Delivers Comprehensive Cancer Diagnosis
- AI Improves Cervical Cancer Screening in Low-Resource Settings
- New Multi-Omics Tool Illuminates Cancer Progression
- New Technique Detects Genetic Mutations in Brain Tumors During Surgery within 25 Minutes
- New Imaging Tech to Improve Diagnosis and Treatment of Skin Cancers
- Serially Testing Brain Tumor Samples Reveals Treatment Response in Glioblastoma Patients
- High-Accuracy Tumor Detection Method Offers Real-Time Surgical Guidance
- AI Tool Detects Hidden Warning Signs of Disease Inside Single Cells
- Automated Tool Detects Early Warning Signs of Breast Cancer
- New Software Tool Improves Analysis of Complex Spatial Data from Tissues
- AI Tool Helps Surgeons Distinguish Aggressive Glioblastoma from Other Brain Cancers in Real-Time
- New Tool Could Revolutionize Acute Leukemia Diagnosis
- New Microscope Promises to Speed Up Medical Diagnostics
Channels
Clinical Chemistry
view channel
VOCs Show Promise for Early Multi-Cancer Detection
Early cancer detection is critical to improving survival rates, but most current screening methods focus on individual cancer types and often involve invasive procedures. This makes it difficult to identify... Read more
Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
Kidney disease is typically diagnosed through blood or urine tests, often when patients present with symptoms such as blood in urine, shortness of breath, or weight loss. While these tests are common,... Read more
Molecular Diagnostics
view channel
Genomic Test Could Reduce Lymph Node Biopsy Surgery in Melanoma Patients
Accurately determining whether melanoma has spread to the lymph nodes is crucial for guiding treatment decisions, yet the standard procedure—sentinel lymph node biopsy—remains invasive, costly, and unnecessary... Read more
Urine Test Could Replace Painful Kidney Biopsies for Lupus Patients
Lupus is an autoimmune disorder that causes the immune system to attack the body’s own tissues and organs. Among the five million people living with lupus globally, nearly half develop lupus nephritis,... Read more
Blood Test Guides Post-Surgical Immunotherapy for Muscle-Invasive Bladder Cancer
After surgery for muscle-invasive bladder cancer, many patients face uncertainty about whether residual cancer cells remain in their bodies. Now, a new international phase 3 study has demonstrated that... Read more
Mitochondrial DNA Mutations from Kidney Stressors Could Predict Future Organ Decline
Kidney-related diseases are alarmingly common: chronic kidney disease (CKD) affects more than one in seven U.S. adults, while about 20% of hospitalized adults are diagnosed with acute kidney injury (AKI).... Read moreHematology
view channel
Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more
Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more
Platelets Could Improve Early and Minimally Invasive Detection of Cancer
Platelets are widely recognized for their role in blood clotting and scab formation, but they also play a crucial role in immune defense by detecting pathogens and recruiting immune cells.... Read more
Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment
Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read moreImmunology
view channel
Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
Immunotherapy has revolutionized cancer care by harnessing the immune system to fight tumors, yet predicting who will benefit remains a major challenge. Many patients undergo costly and taxing treatment... Read more
Signature Genes Predict T-Cell Expansion in Cancer Immunotherapy
Modern cancer immunotherapies rely on the ability of CD8⁺ T cells to rapidly multiply within tumors, generating the immune force needed to eliminate cancer cells. However, the biological triggers behind... Read more
Microbiology
view channel
Fast Noninvasive Bedside Test Uses Sugar Fingerprint to Detect Fungal Infections
Candida bloodstream infections are a growing global health threat, causing an estimated 6 million cases and 3.8 million deaths annually. Hospitals are particularly vulnerable, as weakened patients after... Read more
Rapid Sepsis Diagnostic Device to Enable Personalized Critical Care for ICU Patients
Sepsis is a life-threatening condition that occurs when the body’s response to infection spirals out of control, damaging organs and leading to critical illness. Patients often arrive at intensive care... Read more
Technology
view channel
Embedded GPU Platform Enables Rapid Blood Profiling for POC Diagnostics
Blood tests remain a cornerstone of medical diagnostics, but traditional imaging and analysis methods can be slow, costly, and reliant on dyes or contrast agents. Now, scientists have developed a real-time,... Read more
Viral Biosensor Test Simultaneously Detects Hepatitis and HIV
Globally, over 300 million people live with Hepatitis B and C, and 40 million with HIV, according to WHO estimates. Diagnosing bloodborne viruses such as HIV and Hepatitis B and C remains challenging in... Read more
Industry
view channel
Advanced Instruments Merged Under Nova Biomedical Name
Advanced Instruments (Norwood, MA, USA) and Nova Biomedical (Waltham, MA, USA) are now officially doing business under a single, unified brand. This transformation is expected to deliver greater value... Read more
